Ibrutinib and Nivolumab in Treating Participants With Metastatic Solid Tumors

Inclusion Criteria: * Patients with biopsy-proven metastatic solid tumor and be eligible to receive nivolumab per standard of care * Patients will be allowed to have any number of prior lines of therapy for metastatic cancer * Patients with measurable and non-measurable disease are allowed to participate * Absolute neutrophil count (ANC) ? 1.5 x 10\^3/mm\^3 * Hemoglobin (Hgb) ? 9 g/dL * Platelet count ? 100 x10\^3/mm\^3 * Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ? 2.5 x upper limit of normal (ULN) or ? 5 x ULN in patients with liver metastases * Prothrombin time ? 1.5 x ULN * Total bilirubin ? 1.5 x ULN (unconjugated bilirubin of \< 3 x ULN for patients with known Gilbert syndrome) * Creatinine clearance of ? 50 ml/min by Cockcroft-Gault equation * Corrected QT interval of \< 480 msec (using either Bazett?s or Fridericia's formula) * Life expectancy of \> 12 weeks * Eastern Cooperative Oncology Group (ECOG) performance status 0 ? 2 * Sexually active women with child bearing potential must have a negative pregnancy test obtained within 14 days prior to initiating study treatment * Sexually active women of child-bearing potential and men must agree to use adequate contraception prior to study entry, for the duration of study participation and for 3 months after completion of study treatment administration; adequate contraception includes methods such as oral contraceptives, double barrier method (condom plus spermicide or diaphragm), or abstaining from sexual intercourse Exclusion Criteria: * History of prior therapy with ibrutinib or nivolumab * Unable to swallow capsules or having disease that is significantly affecting gastrointestinal function and/or inhibiting small intestine absorption * Diagnosis of congenital or acquired immunodeficiency with the exception of chemotherapy induced immune suppression * Active autoimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids of greater than or equal to prednisone 10 mg/day or other immunosuppressive agents; patients with history of adequately treated Hashimoto?s thyroiditis will be eligible; patients requiring a short course of a high dose prednisone burst to treat asthma or common obstructive pulmonary disease will also be eligible 5 days following completion of the prednisone treatment * Use of systemic steroids at a dose above 10 mg/day of prednisone or prednisone equivalent in cycle 1 of study therapy; systemic steroids must be discontinued at least 5 days prior to initiating study therapy; exception will be given to patients who develop immune related adverse events that necessitate use of steroids or other immune suppressive agents; following cycle 1 of study treatment, the use of systemic steroids will be allowed per discretion of the treating physician * Active, non-infectious pneumonitis * Ongoing or active infection requiring systemic therapy * History of being positive for human immunodeficiency virus (HIV) * History of hepatitis B or C * History of receiving live vaccine within 30 days of planned start of study therapy * Central nervous system (CNS) metastases or leptomeningeal carcinomatosis; patients with history of adequately treated brain metastases that are stable for \> 2 weeks prior to the first dose of study regimen are eligible as long they no longer require steroids and have no seizures or worsening focal neurologic symptoms; anti-epileptic therapy will be allowed * Patients who had prior systemic chemotherapy within 3 weeks (or \< 5 half-lives ? whichever is longer) * Prior radiation therapy within 2 weeks of study enrollment * Prior investigational therapy within 4 weeks * Major surgery within 4 weeks or minor surgery within 2 weeks prior to the first dose of study drug; port placement will not be considered major or minor surgery * Any inter-current, uncontrolled systemic illness or any medical or psychiatric condition that in the opinion of the investigator would make the study therapy unsafe to the patient * Unable to understand and sign informed consent form * Uncontrolled, active cardiovascular disease including, but not limited to: symptomatic congestive heart failure, any class 3 or 4 cardiac disease as defined by the New York Heart Association functional classification, unstable angina pectoris, cardiac arrhythmia * Any medications or substances that are strong inhibitors or inducers of CYP 3A4 need to be discontinued prior to initiation the study therapy and for the duration of ibrutinib treatment; patients can resume these medications 3 days after completion of ibrutinib course * History of allergic reactions attributed to compounds of similar chemical or biologic composition as ibrutinib or nivolumab